RSRitu Sidgal

Ritu Sidgal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Ritu Sidgal has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biopsy-confirmed diffuse exanthematous drug eruption following tirzepatide initiation: A case report

    by Kanika Garg, Joyce J.ZHu, Ritu Sidgal, Abdulrahman M.NAzif

    Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is used to treat type 2 diabetes mellitus. While gastrointestinal adverse effects are well established, cutaneous manifestations are less characterized. We report a case of a biopsy-confirmed exanthematous drug eruption associated with tirzepatide. A 74-year-old woman developed profuse watery diarrhea and an intensely pruritic rash shortly after initiating tirzepatide. Over three weeks, the eruption involved the bilateral upper extremities and proximal lower extremities. Histopathologic evaluation revealed superficial dermal perivascular dermatitis with eosinophils and mild epidermal spongiosis. Discontinuation of tirzepatide and topical corticosteroids led to clinical improvement. This case expands the limited literature on systemic dermatologic adverse effects of tirzepatide by demonstrating a biopsy-confirmed exanthematous drug eruption. Recognition of such reactions allows for prompt diagnosis and enhanced patient counseling. This represents one of the first reported biopsy-confirmed exanthematous drug eruptions associated with tirzepatide. Key words: Tirzepatide, GLP-1 receptor agonist, Cutaneous adverse drug reaction, Obesity pharmacotherapy, Dermatologic toxicity